Disclosed are novel gene therapy constructs containing both HEXA and HEXB genes to treat GM2 gangliosidoses, including Sandhoff disease and Tay-Sachs disease. Also described are co-treatments using chaperone and anti-inflammatory agents to enhance the effects of gene therapy.